Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib versus best supportive care for advanced biliary tract cancer
ChiCTR-IIR-17014202Phase 2Recruiting
- Sponsor
- Hunan Provincial People's Hospital
- Start
- Jan 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in biliary cancer, gallbladder cancer and cholangiocarcinoma (CCA) (2 arms), sponsored by Hunan Provincial People's Hospital. Primary endpoints: Progression-free survival and Overall survival. Started Jan 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
biliary cancergallbladder cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR-IIR-17014202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17014202.